Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13661911 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MMP2ANPEPATMCYP3A4 | |
| SCHEMBL2610758 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MMP2ANPEPATMCYP3A4 | |
| SCHEMBL16376157 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MMP2ANPEPATMCYP3A4 | |
| SCHEMBL18084393 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MMP2ANPEPATMCYP3A4 | |
| SCHEMBL26379162 | 0.86 | PEPD (0.41) | ALDH1A1MMP2ANPEPCYP3A4MAPT | |
| SCHEMBL9969991 | 0.83 | ALDH1A1 (0.40) | ALDH1A1MMP2ANPEPCYP3A4MAPT | |
| SCHEMBL13920579 | 0.82 | KMT2A (0.34) | ALDH1A1ATMCYP3A4MAPTMEN1 | |
| SCHEMBL13920501 | 0.82 | DPP4 (0.35) | ALDH1A1ATM | |
| SCHEMBL18084388 | 0.81 | MMP2 (0.38) | ALDH1A1MMP2ANPEPCYP3A4MAPT | |
| SCHEMBL12795646 | 0.81 | MMP2 (0.38) | ALDH1A1MMP2ANPEPPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9227940-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150005342-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-01 | — | — | US | disclosed |
| US-8889871-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130267713-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-10-10 | — | — | US | disclosed |
| US-8507722-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| US-8435984-B2 | Tertiary amine substituted peptides useful as inhibitors of HCV replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8343477-B2 | Viricides; serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8299094-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100292219-A1 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7741281-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090274656-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-20090082261-A1 | UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-7449479-B2 | Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-7323447-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | ALDH1A1 769/4885MMP2 1627/4885ANPEP 1328/4885 |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | ALDH1A1 3864/4885MMP2 1112/4885ANPEP 209/4885 |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | TERT, VIP, YWHAZ | ALDH1A1 3464/4885MMP2 859/4885ANPEP 217/4885 |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, MRPS23, HCCS | ALDH1A1 4217/4885MMP2 1435/4885ANPEP 264/4885 |
| US-20090274656-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, CTRB1 | ALDH1A1 769/4885MMP2 1627/4885ANPEP 1328/4885 |
| US-20100292219-A1 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION | RTF2, RFC5, EIF2AK2 | ALDH1A1 2021/4885MMP2 2521/4885ANPEP 64/4885 |
| US-20150005342-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | ALDH1A1 769/4885MMP2 1627/4885ANPEP 1328/4885 |
| US-20090082261-A1 | UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | VIP, SLC14A1, RPL35 | ALDH1A1 4465/4885MMP2 2053/4885ANPEP 70/4885 |
| US-20130267713-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | ALDH1A1 769/4885MMP2 1627/4885ANPEP 1328/4885 |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | ALDH1A1 3864/4885MMP2 1112/4885ANPEP 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.